S100A9 and type 1 diabetes mellitus: (2013) reported that S100A8/S100A9 acted through the receptor for advanced glycation end-products (RAGE) on CMPs to promotegranulocyte–macrophage colony-stimulating factor (GM-CSF) production that in turn stimulated GMP proliferation and myelopoiesis in type 1 diabetic mice and apoE−/− mice.